Current treatment in macrophage activation syndrome worldwide: a systematic literature review to inform the METAPHOR project

• Published in: Rheumatology (Oxford, England)
• Main Authors: Baldo, Francesco, Erkens, Remco G A, Mizuta, Mao, Rogani, Greta, Lucioni, Federica, Bracaglia, Claudia, Foell, Dirk, Gattorno, Marco, Jelusic, Marija, Anton, Jordi, Brogan, Paul, Canna, Scott, Chandrakasan, Shanmuganathan, Cron, Randy Q, De Benedetti, Fabrizio, Grom, Alexei, Heshin-Bekenstein, Merav, Horne, AnnaCarin, Khubchandani, Raju, Ozen, Seza, Quartier, Pierre, Ravelli, Angelo, Shimizu, Masaki, Schulert, Grant, Scott, Christiaan, Sinha, Rashmi, Ruperto, Nicolino, Swart, Joost F, Vastert, Sebastiaan, Minoia, Francesca
• Format: Journal Article
• Language: English
• Published: England 26.07.2024
• Subjects: Medicin och hälsovetenskap; haemophagocytic lymphohistiocytosis; macrophage activation syndrome; treatment; haemophagocytic syndromes
• ISSN: 1462-0324; 1462-0332; 1462-0332
• DOI: 10.1093/rheumatology/keae391

To assess current treatment in macrophage activation syndrome (MAS) worldwide and to highlight any areas of major heterogeneity of practice. A systematic literature search was performed in both Embase and PubMed databases. Paper screening was done by two independent teams based on agreed criteria. Data extraction was standardized following the PICO framework. A panel of experts assessed paper validity, using the Joanna Briggs Institute appraisal tools and category of evidence (CoE) according to EULAR procedure. Fifty-seven papers were finally included (80% retrospective case-series), describing 1148 patients with MAS: 889 systemic juvenile idiopathic arthritis (sJIA), 137 systemic lupus erythematosus (SLE), 69 Kawasaki disease (KD) and 53 other rheumatologic conditions. Fourteen and 11 studies specified data on MAS associated to SLE and KD, respectively. All papers mentioned glucocorticoids (GCs), mostly methylprednisolone and prednisolone (90%); dexamethasone was used in 7% of patients. Ciclosporin was reported in a wide range of patients according to different cohorts. Anakinra was used in 179 MAS patients, with a favourable outcome in 83% of sJIA-MAS. Etoposide was described by 11 studies, mainly as part of HLH-94/04 protocol. Emapalumab was the only medication tested in a clinical trial in 14 sJIA-MAS, with 93% of MAS remission. Ruxolitinib was the most reported JAK-inhibitor in MAS. High-dose GCs together with IL-1 and IFNγ inhibitors have shown efficacy in MAS, especially in sJIA-associated MAS. However, global level of evidence on MAS treatment, especially in other conditions, is still poor and requires standardized studies to be confirmed.